GCL
ATXS

Glazer Capital LLC’s Astria Therapeutics ATXS Stock Holding History

Glazer Capital LLC’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,776,154
Closed -$49.4M – 485
2025
Q4 		$49.4M Buy
+3,776,154
New +$45.1M 1.3% 17

Glazer Capital LLC's ATXS Position: Q1 2026 in Review

Glazer Capital LLC sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 3,776,154 shares — an estimated $49.4M sold.

Glazer Capital LLC first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $49.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Glazer Capital LLC reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Glazer Capital LLC sold 3,776,154 Astria Therapeutics shares in Q1 2026, an estimated $49.4M.
  • Glazer Capital LLC first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
  • Glazer Capital LLC's Astria Therapeutics position peaked at $49.4M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Glazer Capital LLC's 13F filing for Q1 2026, filed 14 May 2026.